Phosphoglycerate kinase is a central leverage point in Parkinson’s Disease driven neuronal metabolic deficits

Phosphoglycerate kinase 1 (PGK1), the first ATP producing glycolytic enzyme, has emerged as a therapeutic target for Parkinson’s Disease (PD), since a potential enhancer of its activity was reported to significantly lower PD risk. We carried out a suppressor screen of hypometabolic synaptic deficits...

Descripción completa

Detalles Bibliográficos
Autores principales: Kokotos, Alexandros C., Antoniazzi, Aldana M., Unda, Santiago R., Ko, Myung Soo, Park, Daehun, Eliezer, David, Kaplitt, Michael G., Camilli, Pietro De, Ryan, Timothy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592794/
https://www.ncbi.nlm.nih.gov/pubmed/37873141
http://dx.doi.org/10.1101/2023.10.10.561760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592794/
https://www.ncbi.nlm.nih.gov/pubmed/37873141
http://dx.doi.org/10.1101/2023.10.10.561760

Ejemplares similares